clinical trial · NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 43
Follicular LymphomaMarginal Zone LymphomaB-Cell LymphomaZanubrutinibRituximab
brief summary
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
started
Apr 19, 2024
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Feb 5, 2026
official title
A Phase 2 Open-Label, Multicenter Study of Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol